Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio (2011 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Interest Coverage Ratio of 3.88 for Q1 2026, down 99.71% on a QoQ basis from 1317.18 in Q4 2025, and up 1378.45% year-over-year from 0.26 in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Interest Coverage Ratio history runs 14 years deep, the most recent figure standing at 3.88 for Q1 2026.
- Quarterly Interest Coverage Ratio rose 1378.45% year-over-year to 3.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.88 (up 1044.57% YoY) and the FY2025 annual result came in at 1.99, up 3230.44% from the prior year.
- Interest Coverage Ratio was 3.88 for Q1 2026 at Alnylam Pharmaceuticals, down from 1317.18 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1317.18 in Q4 2025 and bottomed at 7.65 in Q2 2023.
- A 5-year average of 76.88 and a median of 1.21 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio plunged 154.15% — and 2025, when it soared 108584.26%.
- Alnylam Pharmaceuticals' Interest Coverage Ratio stood at 2.27 in 2022, then plunged by 154.15% to 1.23 in 2023, then rose by 1.38% to 1.21 in 2024, then soared by 108584.26% to 1317.18 in 2025, then sank by 99.71% to 3.88 in 2026.
- Business Quant data shows ALNY's Interest Coverage Ratio at 3.88 in Q1 2026, 1317.18 in Q4 2025, and 8.29 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 3.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.88 |
| Dec 31, 2025 | 1,317.18 |
| Sep 30, 2025 | 8.29 |
| Jun 30, 2025 | -0.40 |
| Mar 31, 2025 | 0.26 |
| Dec 31, 2024 | -1.21 |
| Sep 30, 2024 | -2.24 |
| Jun 30, 2024 | 1.46 |
| Mar 31, 2024 | -1.23 |
| Dec 31, 2023 | -1.23 |
| Sep 30, 2023 | 6.92 |
| Jun 30, 2023 | -7.65 |
| Mar 31, 2023 | -5.17 |
| Dec 31, 2022 | 2.27 |
| Sep 30, 2022 | -6.28 |
| Jun 30, 2022 | -4.50 |
| Mar 31, 2022 | -3.46 |
| Dec 31, 2021 | -5.28 |
| Sep 30, 2021 | -4.51 |
| Jun 30, 2021 | -4.37 |